Evaluation of effervescent floating matrix tablet formulations of salbutamol sulfate using full factorial design

Main Article Content

Monica RP Rao
Girish S Sonar
Rachana R Mandsaurwale
Swapnila D Vanshiv


The purpose of this research was to formulate and optimize an effervescent floating tablet formulation of salbutamol
sulfate using full factorial design. Salbutamol sulfate has an absorption window in the stomach and in the upper part
of the small intestine. A 32 full factorial design (eight runs) was utilized to optimize the formulation wherein the content of
hydroxylpropyl methyl cellulose (HPMC) (X1) and sodium bicarbonate (X2) were taken as independent variables and % drug
release after 6 h (Y1), t50% (Y2), and buoyancy lag time (BLT) (Y3) were taken as the dependent variables. Salbutamol sufate,
HPMC K4M and HPMC K100M CR, stearic acid, talc, dicalcium phosphate, polyvinyl pyrrolidone, and magnesium stearate
were used for the current research work. Two viscosity grades of HPMC as matrix materials were used for formulating the
tablets, which were prepared by wet granulation. The release data were evaluated by the model-dependent (curve fitting)
method using the PCP Disso v2.08 software. Optimization studies were carried out using the Design Expert Software (Version
7.0.3). The in vitro drug release mechanism showed anomalous transport. An increase in the concentration and viscosity
grade of the polymer resulted in a decrease in the release rate, but it was found that at a higher concentration of HPMC,
the viscosity grade did not significantly affect the drug release. Concentration of both HPMC and sodium bicarbonate had a
significant effect on the BLT. Optimized effervescent floating tablets of salbutamol sulfate were successfully prepared and a
good correlation was observed between predicted and actual values of the dependent variables chosen for the study. Viscosity
grade of HPMC did not significantly impact the floatability of the dosage form. Thus, we can conclude that a combination of
HPMC, stearic acid, and sodium bicarbonate can be used to increase the gastric residence time of the dosage form up to 12 h.


Download data is not yet available.

Article Details

How to Cite
Rao, M. R., Sonar, G. S., Mandsaurwale, R. R., & Vanshiv, S. D. (2014). Evaluation of effervescent floating matrix tablet formulations of salbutamol sulfate using full factorial design. Asian Journal of Pharmaceutics (AJP), 3(1). https://doi.org/10.22377/ajp.v3i1.240


Reynolds JE. Martindale-the extra Pharmacopoeia. Great Britain:

Director of the Council of Royal Pharmaceutical Society of Great

Britain; 2005. p. 362.

Figure 6: Comparison of release profile of optimized formulations

(G3 and G5) and marketed SR tablet (Asthalin SA-8, Cipla)

Swarbrick J, Boylon JC. Encyclopedia of Pharmaceutical Technology.

New York: Marcel Dekker Inc; 200. p. 896.

Lipworth BJ, Clark RA, Dhillon DP, Charter MK, Palmer JB, McDevitt DG.

Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral

salbutamol controlled-release in patients with bronchial asthama.

Eur J Clin Pharmacol 1989;37:49-52.

Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute

bioavailability of albutamol in healthy adult volunteers. Eur J Clin

Pharmacol 1987;32:631-4.

Pacifici GM, Giulianetti B, Quilici MC, Spisni R, Nervi M, Giuliani L,

et al. (-)-Salbutamol sulphation in the human liver and duodenal

mucosa: interindividual variability. Xenobiotica 1997;27:279-86.

Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel

sustained release, swellable and bioadhesive gastroretentive drug

delivery system for ofloxacin. Int J Pharm 2006;316:86-92.

Singh BN, Kim KH. Floating drug delivery systems: An approach to

oral controlled drug delivery via gastric retention. J Control Release


Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems.

Crit Rev Ther Drug Carrier Syst 1998;15:243-84.

Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive

dosage forms: Overview and special case of Helicobactor pylori.

J Control Rel 2006;111:1-18.

Rouge N, Buri P, Doelkar E. Drug absorption sites in the

gastrointestinal tract and dosage for site-specific delivery. Int J

Pharm 1996;136:117-39.

Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating microspheres

bearing acetohyxamic acid for the treatment of Helicobactor pylori.

J Pharm Pharmacol 2003;55:607-13.

Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based

microsheres of rapiglinide for gastroretentive floating drug

delivery: Preparation and in vitro characterization. J Control Rel


Garg S, Sharma S. Gastroretentive drug delivery systems. Business

Brief Pharmatech 5th ed. Available from: http://www.touchbriefings.

com/cdps/cditem.cfm?NID-17andCID-5. [cited in 2003].

Singh B, Ahuja N. Response surface optimization of drug delivery

system. In: Jain NK, editor. Progress in Controlled and Novel Drug

Delivery System. New Delhi: CBS Publishers and Distributors; 2004.

p. 470-509.

Singh B, Ahuja N. Development of controlled-release buccoadhesive

hydrophilic matrices of diltiazem hydrochloride: optimization of

bioadhesive, dissolution, and diffusion parameters. Drug Dev Ind

Pharm 2002;28:431-42.

Siepmam J, Peppas NA. Modelling of drug release from delivery

systems based on hydroxypropyl methyl cellulose (HPMC). Adv Drug

Del Rel 2001;48:139-57.

Ritger PL, Peppas NA. A simple equation for description of solute

release II. Fickian and anomalous release from swellable devices.

J Control Release 1987;5:7-42.